25 XP   0   0   10

Biomerieux SA
Buy, Hold or Sell?

Let's analyse Biomerieux together

PenkeI guess you are interested in Biomerieux SA. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Biomerieux SA. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Biomerieux SA

I send you an email if I find something interesting about Biomerieux SA.

Quick analysis of Biomerieux (30 sec.)










What can you expect buying and holding a share of Biomerieux? (30 sec.)

How much money do you get?

How much money do you get?
€1.53
When do you have the money?
1 year
How often do you get paid?
90.6%

What is your share worth?

Current worth
€31.76
Expected worth in 1 year
€33.13
How sure are you?
87.5%

+ What do you gain per year?

Total Gains per Share
€2.78
Return On Investment
2.7%

For what price can you sell your share?

Current Price per Share
€102.25
Expected price per share
€94.82 - €105.95
How sure are you?
50%

1. Valuation of Biomerieux (5 min.)




Live pricePrice per Share (EOD)

€102.25

Intrinsic Value Per Share

€33.69 - €39.18

Total Value Per Share

€65.46 - €70.94

2. Growth of Biomerieux (5 min.)




Is Biomerieux growing?

Current yearPrevious yearGrowGrow %
How rich?$4b$2.4b$566.3m18.9%

How much money is Biomerieux making?

Current yearPrevious yearGrowGrow %
Making money$168.6m$181.8m-$13.2m-7.8%
Net Profit Margin6.5%12.5%--

How much money comes from the company's main activities?

3. Financial Health of Biomerieux (5 min.)




4. Comparing to competitors in the Diagnostics & Research industry (5 min.)




  Industry Rankings (Diagnostics & Research)  


Richest
#13 / 148

Most Revenue
#12 / 148

Most Profit
#12 / 148

What can you expect buying and holding a share of Biomerieux? (5 min.)

Welcome investor! Biomerieux's management wants to use your money to grow the business. In return you get a share of Biomerieux.

What can you expect buying and holding a share of Biomerieux?

First you should know what it really means to hold a share of Biomerieux. And how you can make/lose money.

Speculation

The Price per Share of Biomerieux is €102.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biomerieux.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biomerieux, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €31.76. Based on the TTM, the Book Value Change Per Share is €0.34 per quarter. Based on the YOY, the Book Value Change Per Share is €1.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.35 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biomerieux.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps1.791.8%1.091.1%1.541.5%1.111.1%0.860.8%
Usd Book Value Change Per Share1.151.1%0.370.4%1.101.1%0.840.8%0.730.7%
Usd Dividend Per Share0.000.0%0.380.4%0.230.2%0.220.2%0.180.2%
Usd Total Gains Per Share1.151.1%0.750.7%1.331.3%1.071.0%0.910.9%
Usd Price Per Share108.82-105.91-99.86-106.40-108.33-
Price to Earnings Ratio15.16-28.71-18.17-27.12-41.62-
Price-to-Total Gains Ratio94.59-31.46--0.12-81.54-289.54-
Price to Book Ratio3.17-6.32-7.40-5.61-6.35-
Price-to-Total Gains Ratio94.59-31.46--0.12-81.54-289.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share110.603825
Number of shares9
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.380.22
Usd Book Value Change Per Share0.370.84
Usd Total Gains Per Share0.751.07
Gains per Quarter (9 shares)6.769.60
Gains per Year (9 shares)27.0338.41
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
114131783028
2272744166166
34140712491104
455539832121142
5696612540152180
6828015248182218
7969317956212256
811010620665243294
912412023373273332
1013713326081303370

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.00.00.0100.0%11.00.00.0100.0%19.00.00.0100.0%32.00.00.0100.0%34.00.02.094.4%
Book Value Change Per Share2.01.00.066.7%6.03.02.054.5%10.04.05.052.6%20.05.07.062.5%24.05.07.066.7%
Dividend per Share2.00.01.066.7%10.00.01.090.9%16.00.03.084.2%29.00.03.090.6%33.00.03.091.7%
Total Gains per Share2.01.00.066.7%8.03.00.072.7%15.04.00.078.9%28.04.00.087.5%32.04.00.088.9%

Fundamentals of Biomerieux

About Biomerieux SA

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

Fundamental data was last updated by Penke on 2024-03-18 22:24:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Biomerieux SA.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biomerieux earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • A Net Profit Margin of 10.3% means that €0.10 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Biomerieux SA:

  • The MRQ is 10.3%. The company is making a huge profit. +2
  • The TTM is 6.5%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ10.3%TTM6.5%+3.8%
TTM6.5%YOY12.5%-6.0%
TTM6.5%5Y6.8%-0.3%
5Y6.8%10Y7.2%-0.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ10.3%-5.2%+15.5%
TTM6.5%-6.0%+12.5%
YOY12.5%-1.8%+14.3%
5Y6.8%-8.0%+14.8%
10Y7.2%-4.4%+11.6%
1.1.2. Return on Assets

Shows how efficient Biomerieux is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • 3.7% Return on Assets means that Biomerieux generated €0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Biomerieux SA:

  • The MRQ is 3.7%. Using its assets, the company is less efficient in making profit.
  • The TTM is 5.1%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ3.7%TTM5.1%-1.4%
TTM5.1%YOY6.5%-1.3%
TTM5.1%5Y4.0%+1.1%
5Y4.0%10Y3.1%+0.9%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7%-0.9%+4.6%
TTM5.1%-0.8%+5.9%
YOY6.5%-1.3%+7.8%
5Y4.0%-1.2%+5.2%
10Y3.1%-0.8%+3.9%
1.1.3. Return on Equity

Shows how efficient Biomerieux is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • 5.2% Return on Equity means Biomerieux generated €0.05 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Biomerieux SA:

  • The MRQ is 5.2%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 7.3%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ5.2%TTM7.3%-2.0%
TTM7.3%YOY9.2%-2.0%
TTM7.3%5Y6.1%+1.2%
5Y6.1%10Y4.7%+1.4%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ5.2%-0.4%+5.6%
TTM7.3%-0.3%+7.6%
YOY9.2%-1.0%+10.2%
5Y6.1%-1.7%+7.8%
10Y4.7%-2.1%+6.8%

1.2. Operating Efficiency of Biomerieux SA.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biomerieux is operating .

  • Measures how much profit Biomerieux makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • An Operating Margin of 10.7% means the company generated €0.11  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Biomerieux SA:

  • The MRQ is 10.7%. The company is operating less efficient.
  • The TTM is 7.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ10.7%TTM7.1%+3.6%
TTM7.1%YOY15.7%-8.6%
TTM7.1%5Y8.6%-1.6%
5Y8.6%10Y9.7%-1.0%
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ10.7%-9.4%+20.1%
TTM7.1%-0.1%+7.2%
YOY15.7%3.3%+12.4%
5Y8.6%0.3%+8.3%
10Y9.7%-2.7%+12.4%
1.2.2. Operating Ratio

Measures how efficient Biomerieux is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • An Operation Ratio of 0.89 means that the operating costs are €0.89 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Biomerieux SA:

  • The MRQ is 0.893. The company is less efficient in keeping operating costs low.
  • The TTM is 0.596. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.893TTM0.596+0.297
TTM0.596YOY0.448+0.147
TTM0.5965Y0.504+0.091
5Y0.50410Y0.713-0.208
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8931.307-0.414
TTM0.5961.299-0.703
YOY0.4481.277-0.829
5Y0.5041.246-0.742
10Y0.7131.215-0.502

1.3. Liquidity of Biomerieux SA.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biomerieux is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A Current Ratio of 2.03 means the company has €2.03 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Biomerieux SA:

  • The MRQ is 2.028. The company is able to pay all its short-term debts. +1
  • The TTM is 2.061. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.028TTM2.061-0.033
TTM2.061YOY1.974+0.087
TTM2.0615Y1.853+0.208
5Y1.85310Y1.822+0.031
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0282.183-0.155
TTM2.0612.341-0.280
YOY1.9742.625-0.651
5Y1.8532.989-1.136
10Y1.8222.958-1.136
1.3.2. Quick Ratio

Measures if Biomerieux is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • A Quick Ratio of 1.19 means the company can pay off €1.19 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Biomerieux SA:

  • The MRQ is 1.193. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 2.054. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.193TTM2.054-0.861
TTM2.054YOY2.433-0.379
TTM2.0545Y1.401+0.653
5Y1.40110Y1.095+0.306
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1931.310-0.117
TTM2.0541.437+0.617
YOY2.4331.764+0.669
5Y1.4011.952-0.551
10Y1.0952.080-0.985

1.4. Solvency of Biomerieux SA.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biomerieux assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biomerieux to Diagnostics & Research industry mean.
  • A Debt to Asset Ratio of 0.29 means that Biomerieux assets are financed with 28.7% credit (debt) and the remaining percentage (100% - 28.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Biomerieux SA:

  • The MRQ is 0.287. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.287. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.2870.000
TTM0.287YOY0.299-0.012
TTM0.2875Y0.351-0.064
5Y0.35110Y0.384-0.033
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2870.432-0.145
TTM0.2870.431-0.144
YOY0.2990.377-0.078
5Y0.3510.443-0.092
10Y0.3840.446-0.062
1.4.2. Debt to Equity Ratio

Measures if Biomerieux is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biomerieux to the Diagnostics & Research industry mean.
  • A Debt to Equity ratio of 40.2% means that company has €0.40 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Biomerieux SA:

  • The MRQ is 0.402. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.403. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.402TTM0.403-0.001
TTM0.403YOY0.429-0.026
TTM0.4035Y0.559-0.156
5Y0.55910Y0.565-0.006
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4020.606-0.204
TTM0.4030.595-0.192
YOY0.4290.603-0.174
5Y0.5590.636-0.077
10Y0.5650.730-0.165

2. Market Valuation of Biomerieux SA

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Biomerieux generates.

  • Above 15 is considered overpriced but always compare Biomerieux to the Diagnostics & Research industry mean.
  • A PE ratio of 15.16 means the investor is paying €15.16 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Biomerieux SA:

  • The EOD is 15.406. Based on the earnings, the company is fair priced.
  • The MRQ is 15.157. Based on the earnings, the company is fair priced.
  • The TTM is 28.705. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD15.406MRQ15.157+0.249
MRQ15.157TTM28.705-13.548
TTM28.705YOY18.175+10.530
TTM28.7055Y27.124+1.581
5Y27.12410Y41.622-14.498
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD15.406-0.293+15.699
MRQ15.157-0.567+15.724
TTM28.705-0.341+29.046
YOY18.175-0.242+18.417
5Y27.124-0.129+27.253
10Y41.6223.396+38.226
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Biomerieux SA:

  • The EOD is 27.576. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 27.131. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -366.424. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD27.576MRQ27.131+0.445
MRQ27.131TTM-366.424+393.555
TTM-366.424YOY58.143-424.567
TTM-366.4245Y-17.494-348.930
5Y-17.49410Y21.943-39.437
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD27.576-0.416+27.992
MRQ27.131-0.917+28.048
TTM-366.424-1.986-364.438
YOY58.143-3.236+61.379
5Y-17.494-2.150-15.344
10Y21.943-3.427+25.370
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biomerieux is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Diagnostics & Research industry mean).
  • A PB ratio of 3.17 means the investor is paying €3.17 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Biomerieux SA:

  • The EOD is 3.219. Based on the equity, the company is fair priced.
  • The MRQ is 3.167. Based on the equity, the company is fair priced.
  • The TTM is 6.320. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.219MRQ3.167+0.052
MRQ3.167TTM6.320-3.153
TTM6.320YOY7.395-1.075
TTM6.3205Y5.612+0.708
5Y5.61210Y6.347-0.735
Compared to industry (Diagnostics & Research)
PeriodCompanyIndustry (mean)+/- 
EOD3.2192.000+1.219
MRQ3.1672.140+1.027
TTM6.3202.120+4.200
YOY7.3953.061+4.334
5Y5.6123.399+2.213
10Y6.3474.128+2.219
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Biomerieux SA compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.0630.342+211%1.020+4%0.779+36%0.674+58%
Book Value Per Share--31.76423.375+36%18.936+68%20.778+53%18.129+75%
Current Ratio--2.0282.061-2%1.974+3%1.853+9%1.822+11%
Debt To Asset Ratio--0.2870.2870%0.299-4%0.351-18%0.384-25%
Debt To Equity Ratio--0.4020.4030%0.429-6%0.559-28%0.565-29%
Dividend Per Share---0.353-100%0.213-100%0.207-100%0.165-100%
Eps--1.6591.007+65%1.422+17%1.027+62%0.793+109%
Free Cash Flow Per Share--0.9270.434+113%0.397+134%0.670+38%0.539+72%
Free Cash Flow To Equity Per Share--0.790-0.058+107%-0.260+133%0.248+219%0.279+183%
Gross Profit Margin--1.0000.266+276%-0.572+157%0.503+99%0.705+42%
Intrinsic Value_10Y_max--39.176--------
Intrinsic Value_10Y_min--33.692--------
Intrinsic Value_1Y_max--3.334--------
Intrinsic Value_1Y_min--3.274--------
Intrinsic Value_3Y_max--10.467--------
Intrinsic Value_3Y_min--9.984--------
Intrinsic Value_5Y_max--18.145--------
Intrinsic Value_5Y_min--16.803--------
Market Cap12078179000.000+2%11883282649.20011605685787.093+2%10954111879.935+8%11647638468.658+2%11850181327.933+0%
Net Profit Margin--0.1030.065+59%0.125-18%0.068+52%0.072+44%
Operating Margin--0.1070.071+51%0.157-32%0.086+24%0.097+11%
Operating Ratio--0.8930.596+50%0.448+99%0.504+77%0.713+25%
Pb Ratio3.219+2%3.1676.320-50%7.395-57%5.612-44%6.347-50%
Pe Ratio15.406+2%15.15728.705-47%18.175-17%27.124-44%41.622-64%
Price Per Share102.250+2%100.60097.907+3%92.315+9%98.360+2%100.152+0%
Price To Free Cash Flow Ratio27.576+2%27.131-366.424+1451%58.143-53%-17.494+164%21.943+24%
Price To Total Gains Ratio96.145+2%94.59431.459+201%-0.122+100%81.541+16%289.544-67%
Quick Ratio--1.1932.054-42%2.433-51%1.401-15%1.095+9%
Return On Assets--0.0370.051-28%0.065-42%0.040-7%0.031+19%
Return On Equity--0.0520.073-28%0.092-43%0.061-14%0.047+12%
Total Gains Per Share--1.0630.694+53%1.233-14%0.986+8%0.839+27%
Usd Book Value--4058646570.0002994262784.167+36%2427916213.750+67%2660536510.395+53%2320117203.047+75%
Usd Book Value Change Per Share--1.1500.369+211%1.103+4%0.843+36%0.729+58%
Usd Book Value Per Share--34.35925.285+36%20.483+68%22.476+53%19.610+75%
Usd Dividend Per Share---0.381-100%0.231-100%0.224-100%0.179-100%
Usd Eps--1.7951.089+65%1.539+17%1.111+62%0.858+109%
Usd Free Cash Flow--118446150.00055599380.000+113%50948070.000+132%85929678.627+38%68982882.232+72%
Usd Free Cash Flow Per Share--1.0030.470+113%0.429+134%0.725+38%0.583+72%
Usd Free Cash Flow To Equity Per Share--0.854-0.063+107%-0.281+133%0.268+219%0.302+183%
Usd Market Cap13064966224.300+2%12854146841.64012553870315.899+2%11849062820.526+8%12599250531.548+2%12818341142.425+0%
Usd Price Per Share110.604+2%108.819105.906+3%99.857+9%106.396+2%108.334+0%
Usd Profit--212013200.000168646044.167+26%181874333.750+17%146916209.342+44%110702699.141+92%
Usd Revenue--2060205820.0001324974330.000+55%1455873551.250+42%770577460.789+167%653990749.531+215%
Usd Total Gains Per Share--1.1500.751+53%1.334-14%1.067+8%0.908+27%
 EOD+4 -4MRQTTM+27 -9YOY+25 -115Y+28 -810Y+30 -6

3.2. Fundamental Score

Let's check the fundamental score of Biomerieux SA based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.406
Price to Book Ratio (EOD)Between0-13.219
Net Profit Margin (MRQ)Greater than00.103
Operating Margin (MRQ)Greater than00.107
Quick Ratio (MRQ)Greater than11.193
Current Ratio (MRQ)Greater than12.028
Debt to Asset Ratio (MRQ)Less than10.287
Debt to Equity Ratio (MRQ)Less than10.402
Return on Equity (MRQ)Greater than0.150.052
Return on Assets (MRQ)Greater than0.050.037
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Biomerieux SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.040
Ma 20Greater thanMa 50100.181
Ma 50Greater thanMa 100101.385
Ma 100Greater thanMa 20099.926
OpenGreater thanClose101.550
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets5,259,200
Total Liabilities1,507,100
Total Stockholder Equity3,752,200
 As reported
Total Liabilities 1,507,100
Total Stockholder Equity+ 3,752,200
Total Assets = 5,259,200

Assets

Total Assets5,259,200
Total Current Assets2,205,200
Long-term Assets3,054,000
Total Current Assets
Cash And Cash Equivalents 352,400
Net Receivables 944,300
Inventory 908,500
Total Current Assets  (as reported)2,205,200
Total Current Assets  (calculated)2,205,200
+/-0
Long-term Assets
Property Plant Equipment 1,506,000
Goodwill 698,800
Intangible Assets 528,600
Long-term Assets Other 7,700
Long-term Assets  (as reported)3,054,000
Long-term Assets  (calculated)2,741,100
+/- 312,900

Liabilities & Shareholders' Equity

Total Current Liabilities1,087,300
Long-term Liabilities419,800
Total Stockholder Equity3,752,200
Total Current Liabilities
Short-term Debt 163,400
Accounts payable 265,100
Other Current Liabilities 606,000
Total Current Liabilities  (as reported)1,087,300
Total Current Liabilities  (calculated)1,034,500
+/- 52,800
Long-term Liabilities
Long-term Liabilities  (as reported)419,800
Long-term Liabilities  (calculated)0
+/- 419,800
Total Stockholder Equity
Common Stock12,000
Retained Earnings 357,600
Other Stockholders Equity 3,382,600
Total Stockholder Equity (as reported)3,752,200
Total Stockholder Equity (calculated)3,752,200
+/-0
Other
Capital Stock12,000
Cash and Short Term Investments 352,400
Common Stock Shares Outstanding 118,124
Current Deferred Revenue52,800
Liabilities and Stockholders Equity 5,259,200
Net Debt 166,400
Net Invested Capital 3,752,200
Net Working Capital 1,117,900
Property Plant and Equipment Gross 1,506,000
Short Long Term Debt Total 518,800



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2023-12-312023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302015-12-312015-06-302014-12-312014-06-302013-12-312013-06-302012-12-312012-06-302011-12-312011-06-302010-12-312010-06-302009-12-31
> Total Assets 
1,259,700
1,385,200
1,448,700
1,470,100
1,762,200
1,807,500
1,833,200
1,840,400
2,196,600
2,327,500
2,580,500
2,674,200
2,773,600
2,758,100
3,028,800
3,028,800
2,923,100
2,923,100
2,990,000
2,990,000
3,007,600
3,007,600
3,389,600
3,389,600
3,647,300
3,647,300
3,781,900
3,782,000
0
4,129,000
0
3,927,900
0
4,157,200
0
4,616,800
1,296,650
5,041,200
1,296,650
5,186,600
1,296,650
5,030,900
5,259,200
5,259,2005,030,9001,296,6505,186,6001,296,6505,041,2001,296,6504,616,80004,157,20003,927,90004,129,00003,782,0003,781,9003,647,3003,647,3003,389,6003,389,6003,007,6003,007,6002,990,0002,990,0002,923,1002,923,1003,028,8003,028,8002,758,1002,773,6002,674,2002,580,5002,327,5002,196,6001,840,4001,833,2001,807,5001,762,2001,470,1001,448,7001,385,2001,259,700
   > Total Current Assets 
610,000
654,400
705,500
767,100
789,900
840,200
890,900
896,700
1,246,700
946,800
1,052,100
1,081,700
1,101,900
1,055,700
1,183,000
1,183,000
1,158,000
1,158,000
1,281,500
1,281,600
1,190,400
1,190,400
1,295,600
1,295,500
1,351,900
1,351,900
1,438,500
1,438,500
1,781,200
1,781,200
1,661,600
1,661,600
1,798,700
1,798,700
2,207,100
2,199,200
554,175
2,058,400
554,175
2,216,700
554,175
2,152,700
2,205,200
2,205,2002,152,700554,1752,216,700554,1752,058,400554,1752,199,2002,207,1001,798,7001,798,7001,661,6001,661,6001,781,2001,781,2001,438,5001,438,5001,351,9001,351,9001,295,5001,295,6001,190,4001,190,4001,281,6001,281,5001,158,0001,158,0001,183,0001,183,0001,055,7001,101,9001,081,7001,052,100946,8001,246,700896,700890,900840,200789,900767,100705,500654,400610,000
       Cash And Cash Equivalents 
47,000
33,500
71,400
82,400
42,700
11,400
65,600
58,500
428,000
95,100
119,700
108,900
147,100
126,300
178,600
178,600
182,200
182,200
312,100
312,100
194,300
194,300
280,100
280,100
247,700
247,700
275,000
275,000
0
589,500
0
389,200
0
493,200
0
803,500
138,150
524,200
138,150
552,600
138,150
423,000
352,400
352,400423,000138,150552,600138,150524,200138,150803,5000493,2000389,2000589,5000275,000275,000247,700247,700280,100280,100194,300194,300312,100312,100182,200182,200178,600178,600126,300147,100108,900119,70095,100428,00058,50065,60011,40042,70082,40071,40033,50047,000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
562,900
562,900
571,300
571,300
549,000
549,000
586,900
586,900
572,200
572,200
623,100
494,800
639,900
639,900
649,800
649,800
682,100
730,400
694,500
694,500
701,400
709,000
825,700
825,700
926,900
865,200
888,900
888,900
944,300
944,300888,900888,900865,200926,900825,700825,700709,000701,400694,500694,500730,400682,100649,800649,800639,900639,900494,800623,100572,200572,200586,900586,900549,000549,000571,300571,300562,900562,90000000000000000
       Inventory 
158,600
184,900
179,500
195,500
217,100
0
245,900
278,500
261,700
302,600
299,200
360,100
355,800
382,900
404,400
404,400
404,400
404,400
380,300
380,300
408,700
408,700
414,900
414,900
481,100
481,100
494,700
494,700
541,900
541,900
541,900
541,900
611,000
611,000
634,600
662,800
184,300
708,500
184,300
767,500
184,300
840,900
908,500
908,500840,900184,300767,500184,300708,500184,300662,800634,600611,000611,000541,900541,900541,900541,900494,700494,700481,100481,100414,900414,900408,700408,700380,300380,300404,400404,400404,400404,400382,900355,800360,100299,200302,600261,700278,500245,9000217,100195,500179,500184,900158,600
   > Long-term Assets 
649,700
730,800
743,200
703,000
972,300
967,300
942,200
943,700
949,900
1,380,700
1,528,300
1,592,300
1,671,600
1,702,400
0
1,845,800
0
1,765,100
0
1,708,400
0
1,817,200
0
2,093,900
0
2,295,400
0
2,343,500
0
2,347,800
0
2,266,300
0
2,358,500
0
2,417,600
742,475
2,982,800
742,475
2,969,900
742,475
2,878,200
3,054,000
3,054,0002,878,200742,4752,969,900742,4752,982,800742,4752,417,60002,358,50002,266,30002,347,80002,343,50002,295,40002,093,90001,817,20001,708,40001,765,10001,845,80001,702,4001,671,6001,592,3001,528,3001,380,700949,900943,700942,200967,300972,300703,000743,200730,800649,700
       Property Plant Equipment 
312,800
333,500
340,100
330,200
367,000
366,300
387,000
386,000
404,900
429,000
486,900
505,500
573,600
614,100
734,500
734,500
712,300
712,300
711,400
711,400
743,800
743,800
807,500
807,500
941,700
941,700
1,025,200
1,025,400
1,041,000
1,041,300
1,068,600
1,068,700
1,135,200
1,135,300
1,224,800
1,224,800
342,475
1,314,400
342,475
1,369,900
342,475
1,392,000
1,506,000
1,506,0001,392,000342,4751,369,900342,4751,314,400342,4751,224,8001,224,8001,135,3001,135,2001,068,7001,068,6001,041,3001,041,0001,025,4001,025,200941,700941,700807,500807,500743,800743,800711,400711,400712,300712,300734,500734,500614,100573,600505,500486,900429,000404,900386,000387,000366,300367,000330,200340,100333,500312,800
       Goodwill 
166,900
188,900
188,700
182,100
334,300
334,300
313,100
309,500
305,000
442,100
437,800
455,000
459,300
455,800
470,600
470,600
454,800
454,800
442,700
442,700
476,100
476,100
616,500
616,500
665,800
665,800
652,500
652,500
0
651,000
0
629,400
0
642,400
0
669,500
203,125
877,500
203,125
812,500
203,125
734,400
698,800
698,800734,400203,125812,500203,125877,500203,125669,5000642,4000629,4000651,0000652,500652,500665,800665,800616,500616,500476,100476,100442,700442,700454,800454,800470,600470,600455,800459,300455,000437,800442,100305,000309,500313,100334,300334,300182,100188,700188,900166,900
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31,200
31,200
46,900
46,900
51,000
51,000
59,100
59,100
59,100
59,100
72,000
72,000
42,100
42,100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000042,10042,10072,00072,00059,10059,10059,10059,10051,00051,00046,90046,90031,20031,20000000000000000
       Intangible Assets 
93,000
115,800
122,700
116,300
184,400
186,500
157,000
155,500
149,700
396,400
460,100
476,600
476,400
471,700
492,600
492,500
454,800
454,700
430,700
430,600
458,100
458,100
507,300
507,400
511,300
511,200
508,400
508,400
0
491,100
0
430,800
0
426,900
0
1,081,000
156,250
1,545,000
156,250
1,437,500
156,250
1,327,000
528,600
528,6001,327,000156,2501,437,500156,2501,545,000156,2501,081,0000426,9000430,8000491,1000508,400508,400511,200511,300507,400507,300458,100458,100430,600430,700454,700454,800492,500492,600471,700476,400476,600460,100396,400149,700155,500157,000186,500184,400116,300122,700115,80093,000
       Long-term Assets Other 
50,900
59,400
66,800
54,100
58,400
56,300
64,100
58,300
56,000
55,000
57,000
61,200
81,900
76,900
0
54,900
0
63,400
0
71,900
0
74,200
0
88,100
0
87,100
0
58,200
0
65,600
0
64,800
0
70,300
0
-648,800
25,725
-857,700
25,725
-799,700
25,725
-727,000
7,700
7,700-727,00025,725-799,70025,725-857,70025,725-648,800070,300064,800065,600058,200087,100088,100074,200071,900063,400054,900076,90081,90061,20057,00055,00056,00058,30064,10056,30058,40054,10066,80059,40050,900
> Total Liabilities 
453,300
475,600
472,600
481,400
658,800
649,700
633,000
635,400
929,300
1,054,300
1,191,800
1,232,600
1,271,000
1,248,100
1,407,500
1,407,500
1,283,400
1,283,400
1,253,300
1,253,300
1,169,000
1,169,000
1,386,300
1,386,300
1,529,900
1,529,900
1,527,300
1,527,300
0
1,721,200
0
1,446,500
0
1,408,200
0
1,442,300
385,925
1,527,400
385,925
1,543,700
385,925
1,389,400
1,507,100
1,507,1001,389,400385,9251,543,700385,9251,527,400385,9251,442,30001,408,20001,446,50001,721,20001,527,3001,527,3001,529,9001,529,9001,386,3001,386,3001,169,0001,169,0001,253,3001,253,3001,283,4001,283,4001,407,5001,407,5001,248,1001,271,0001,232,6001,191,8001,054,300929,300635,400633,000649,700658,800481,400472,600475,600453,300
   > Total Current Liabilities 
388,200
411,100
408,800
412,700
571,800
557,900
534,800
501,600
515,800
540,500
635,700
663,800
689,000
643,900
759,800
759,800
636,900
636,900
651,800
651,900
599,300
599,400
756,400
756,700
823,500
823,400
1,170,100
1,170,200
1,196,500
1,196,500
923,900
923,900
857,900
858,000
955,800
955,800
282,800
1,020,800
282,800
1,131,100
282,800
980,700
1,087,300
1,087,300980,700282,8001,131,100282,8001,020,800282,800955,800955,800858,000857,900923,900923,9001,196,5001,196,5001,170,2001,170,100823,400823,500756,700756,400599,400599,300651,900651,800636,900636,900759,800759,800643,900689,000663,800635,700540,500515,800501,600534,800557,900571,800412,700408,800411,100388,200
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
453,300
453,300
462,500
462,500
6,200
6,200
25,500
25,500
51,300
51,300
86,500
149,300
438,600
438,600
0
443,200
0
128,900
0
163,200
0
99,700
0
226,000
0
187,000
0
160,600
163,400
163,400160,6000187,0000226,000099,7000163,2000128,9000443,2000438,600438,600149,30086,50051,30051,30025,50025,5006,2006,200462,500462,500453,300453,30000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
453,300
453,300
462,500
462,500
6,200
6,200
25,500
25,500
51,300
51,300
86,500
127,500
438,600
438,600
0
420,500
0
0
0
138,600
0
99,700
0
200,600
0
187,000
0
136,100
0
0136,1000187,0000200,600099,7000138,600000420,5000438,600438,600127,50086,50051,30051,30025,50025,5006,2006,200462,500462,500453,300453,30000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
175,600
175,600
152,300
152,300
161,300
161,300
156,700
156,700
176,900
176,900
189,500
189,500
211,900
211,900
201,200
201,200
207,100
207,100
199,100
199,100
239,500
239,500
67,350
243,400
67,350
269,400
67,350
243,500
265,100
265,100243,50067,350269,40067,350243,40067,350239,500239,500199,100199,100207,100207,100201,200201,200211,900211,900189,500189,500176,900176,900156,700156,700161,300161,300152,300152,300175,600175,60000000000000000
       Other Current Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
266,200
266,200
398,900
398,900
194,300
194,300
385,800
385,800
219,700
219,700
484,700
43,100
236,300
519,700
552,100
552,100
260,500
216,200
495,600
468,100
298,700
532,600
215,450
516,800
215,450
586,200
215,450
536,000
606,000
606,000536,000215,450586,200215,450516,800215,450532,600298,700468,100495,600216,200260,500552,100552,100519,700236,30043,100484,700219,700219,700385,800385,800194,300194,300398,900398,900266,200266,20000000000000000
   > Long-term Liabilities 
65,100
64,500
63,800
68,700
87,000
91,800
98,200
133,800
413,500
513,800
556,100
568,800
582,000
604,200
0
647,700
0
646,500
0
601,400
0
569,600
0
629,600
0
706,500
0
357,100
0
524,700
0
522,600
0
550,200
0
486,500
103,125
506,600
103,125
412,600
103,125
408,700
419,800
419,800408,700103,125412,600103,125506,600103,125486,5000550,2000522,6000524,7000357,1000706,5000629,6000569,6000601,4000646,5000647,7000604,200582,000568,800556,100513,800413,500133,80098,20091,80087,00068,70063,80064,50065,100
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
362,800
0
365,700
0
318,400
0
330,100
0
0330,1000318,4000365,7000362,80000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282,300
282,300
269,700
269,700
210,400
210,400
171,100
171,100
183,100
183,100
186,200
186,200
203,500
203,500
186,600
186,600
170,200
170,300
188,800
188,800
123,700
123,600
140,900
140,900
94,200
94,200
78,600
78,600
0
078,60078,60094,20094,200140,900140,900123,600123,700188,800188,800170,300170,200186,600186,600203,500203,500186,200186,200183,100183,100171,100171,100210,400210,400269,700269,700282,300282,30000000000000000
> Total Stockholder Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,619,100
1,619,100
1,637,600
1,637,600
1,737,600
1,737,600
1,838,600
1,838,600
1,929,300
1,929,300
2,065,500
2,117,400
2,203,900
2,203,900
0
2,363,200
0
2,431,100
0
2,698,200
0
3,123,100
910,725
3,469,000
910,725
3,604,200
910,725
3,627,300
3,752,200
3,752,2003,627,300910,7253,604,200910,7253,469,000910,7253,123,10002,698,20002,431,10002,363,20002,203,9002,203,9002,117,4002,065,5001,929,3001,929,3001,838,6001,838,6001,737,6001,737,6001,637,6001,637,6001,619,1001,619,10000000000000000
   Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
12,000
3,000
12,200
3,000
12,000
3,000
12,000
12,000
12,00012,0003,00012,0003,00012,2003,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00012,00000000000000000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
-674,800
-694,500
-682,700
-713,700
-743,300
-802,800
-799,900
-824,300
0
-857,200
0
-866,900
0
-883,000
0
-915,700
0
-958,600
0
-964,600
0
-1,075,700
0
-1,097,200
0
0
0
0
0
3,057,700
0
3,438,100
0
3,554,200
0
3,562,200
0
03,562,20003,554,20003,438,10003,057,70000000-1,097,2000-1,075,7000-964,6000-958,6000-915,7000-883,0000-866,9000-857,2000-824,300-799,900-802,800-743,300-713,700-682,700-694,500-674,800000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,532,100
0
3,174,300
0
3,062,200
0
3,416,300
0
03,416,30003,062,20003,174,30002,532,10000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
511,500
511,500
581,300
581,300
497,400
497,400
680,800
680,800
640,300
640,300
861,900
2,929,500
1,080,600
1,919,100
1,046,200
2,178,300
1,324,700
2,014,700
1,590,100
2,409,100
1,846,600
-547,700
794,625
-1,273,300
794,625
-414,400
58,300
-108,500
3,382,600
3,382,600-108,50058,300-414,400794,625-1,273,300794,625-547,7001,846,6002,409,1001,590,1002,014,7001,324,7002,178,3001,046,2001,919,1001,080,6002,929,500861,900640,300640,300680,800680,800497,400497,400581,300581,300511,500511,50000000000000000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,674,700
Cost of Revenue-1,788,000
Gross Profit1,886,7001,886,700
 
Operating Income (+$)
Gross Profit1,886,700
Operating Expense-1,447,600
Operating Income439,100439,100
 
Operating Expense (+$)
Research Development460,100
Selling General Administrative295,000
Selling And Marketing Expenses725,500
Operating Expense1,447,6001,480,600
 
Net Interest Income (+$)
Interest Income1,400
Interest Expense-0
Other Finance Cost-3,100
Net Interest Income-1,700
 
Pretax Income (+$)
Operating Income439,100
Net Interest Income-1,700
Other Non-Operating Income Expenses0
Income Before Tax (EBT)437,300440,900
EBIT - interestExpense = 439,100
472,100
357,600
Interest Expense0
Earnings Before Interest and Taxes (EBIT)439,100437,300
Earnings Before Interest and Taxes (EBITDA)828,100
 
After tax Income (+$)
Income Before Tax437,300
Tax Provision-114,500
Net Income From Continuing Ops322,900322,800
Net Income357,600
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses3,235,600
Total Other Income/Expenses Net-1,8001,700
 

Technical Analysis of Biomerieux
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biomerieux. The general trend of Biomerieux is BULLISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biomerieux's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (85.7%) Bearish trend (-85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Biomerieux SA.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 103.90 < 105.59 < 105.95.

The bearish price targets are: 96.22 > 96.20 > 94.82.

Tweet this
Biomerieux SA Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Biomerieux SA. The current mas is .

The long score for the Moving Averages is 13/14.
The longshort score for the Moving Averages is 12/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Biomerieux SA Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Biomerieux SA. The current macd is -0.13324247.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biomerieux price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biomerieux. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biomerieux price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Biomerieux SA Daily Moving Average Convergence/Divergence (MACD) ChartBiomerieux SA Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Biomerieux SA. The current adx is 19.67.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Biomerieux shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Biomerieux SA Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Biomerieux SA. The current sar is 96.60.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Biomerieux SA Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Biomerieux SA. The current rsi is 58.04. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
  • Trending up: The RSI is trending up. +1
Biomerieux SA Daily Relative Strength Index (RSI) ChartBiomerieux SA Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Biomerieux SA. The current phase is Overbought in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH > 80: The STOCH %K is above 80 and overbought. +2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biomerieux price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Biomerieux SA Daily Stochastic Oscillator ChartBiomerieux SA Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Biomerieux SA. The current cci is 116.03.

The long score for the Commodity Channel Index (CCI) is 1/1.
The longshort score for the Commodity Channel Index (CCI) is 1/(-1 +1).

  • CCI > 100: The CCI is above 100, it indicates that the price is significantly above its average, suggesting a potential overbought condition. +1
Biomerieux SA Daily Commodity Channel Index (CCI) ChartBiomerieux SA Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Biomerieux SA. The current cmo is 31.42.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Biomerieux SA Daily Chande Momentum Oscillator (CMO) ChartBiomerieux SA Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Biomerieux SA. The current willr is -12.31884058.

The long score for the Williams %R is 1/1.
The longshort score for the Williams %R is 1/(-1 +1).

  • WILLR > -20: The Williams %R is above -20. This indicates that the price is in overbought territory, suggesting a potential price correction or trend reversal to the downside. +1
Biomerieux SA Daily Williams %R ChartBiomerieux SA Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Biomerieux SA.

Biomerieux SA Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Biomerieux SA. The current atr is 1.96593048.

Biomerieux SA Daily Average True Range (ATR) ChartBiomerieux SA Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Biomerieux SA. The current obv is -2,390,705.

Biomerieux SA Daily On-Balance Volume (OBV) ChartBiomerieux SA Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Biomerieux SA. The current mfi is 46.06.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Biomerieux SA Daily Money Flow Index (MFI) ChartBiomerieux SA Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Biomerieux SA.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-10STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-14CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-07CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-09SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside

6.3. Candlestick Patterns

Biomerieux SA Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Biomerieux SA based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.040
Ma 20Greater thanMa 50100.181
Ma 50Greater thanMa 100101.385
Ma 100Greater thanMa 20099.926
OpenGreater thanClose101.550
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biomerieux with someone you think should read this too:
  • Are you bullish or bearish on Biomerieux? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biomerieux? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Biomerieux SA

I send you an email if I find something interesting about Biomerieux SA.


Comments

How you think about this?

Leave a comment

Stay informed about Biomerieux SA.

Receive notifications about Biomerieux SA in your mailbox!